AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12556405
Drug: Enalapril (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (angiotensin converting enzyme inhibitor)
Trial: 2121911
Drug: 18 or
RxNorm normalized name: Panlor Reformulated Jan 2018 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 or 24 Gy radiation therapy (RT) to gonads (group 1)
Trial: 31682027
Drug: Granular slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granular slow-release enteric-coated PAS 4 g twice daily
Trial: 31682027
Drug: Granular slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granular slow-release enteric-coated PAS 8 g once daily
Trial: 28430910
Drug: Pitavastatin plus
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin plus ezetimibe (intensive LDL-C lowering, target LDL-C < 70 mg/dL)
Trial: 28430910
Drug: Pitavastatin monotherapy
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin monotherapy (standard LDL-C lowering, target LDL-C 90-100 mg/dL)
Trial: 28430910
Drug: Pitavastatin plus
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin plus ezetimibe (in patients with higher cholesterol absorption)
Trial: 19111995
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality relaxation plus intravenous morphine PCA infusion
Trial: 19111995
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine PCA infusion alone
Trial: 15297305
Drug: Multiple intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple intervention including group education meetings, consensus procedure on antibiotic indication and type, communication skills training, monitoring and feedback on prescribing behaviour, education for assistants and pharmacists, and educational material for patients.
Trial: 11890487
Drug: Haloperidol 1
RxNorm normalized name: haloperidol 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 1 to 5 mg/day
Trial: 11890487
Drug: Trazodone 50
RxNorm normalized name: traZODone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 50 to 250 mg/day
Trial: 9673476
Drug: Polyacrylic acid
RxNorm normalized name: polyacrylic acid sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyacrylic acid 0.2% (PAA) gel
Trial: 7989638
Drug: Three-phase sequential
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-phase sequential treatment strategy
Trial: 28121041
Drug: Extended antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended antibiotic prophylaxis (intravenous cefuroxime 750 mg plus metronidazole 500 mg, three times daily for 3 days after surgery)
Trial: 28121041
Drug: Standard prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylaxis (single preoperative dose of cefazolin 2000 mg)
Trial: 28121041
Drug: Extended antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended antibiotic prophylaxis
Trial: 8845664
Drug: Transfer Factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer Factor (TF), administered subcutaneously daily for 3 to 4 days during the acute phase, followed by maintenance dosages at 15-day intervals for the first 6 months and monthly thereafter.
Trial: 2667687
Drug: Heater probe
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heater probe therapy (n = 20)
Trial: 29741923
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (n = 23)
Trial: 29153730
Drug: Intranasal ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketorolac (31.5 mg) with nitrous oxide/oxygen
Trial: 29153730
Drug: Intranasal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal saline placebo with nitrous oxide/oxygen
Trial: 20889877
Drug: Iron (2
RxNorm normalized name: prenatal#50/iron fum,bisgly/FA 25 mg iron (23 mg-2 mg)-1 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (2 mg/kg/day) plus folate (5 mg/day)
Trial: 17332786
Drug: Regular physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular physical activity (e.g., brisk walking for at least 30 min daily)
Trial: 24226492
Drug: Morphine (standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (standardized dose 30 minutes before the end of surgery)
Trial: 21279704
Drug: NACT +
RxNorm normalized name: Nacton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NACT + radiotherapy (RT) + adjuvant chemotherapy (AC)
Trial: 19416133
Drug: Lansoprazole maintenance
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole maintenance therapy for up to 82 months
Trial: 17522560
Drug: Oral aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral aripiprazole 10-15 mg/day (n = 153)
Trial: 17522560
Drug: Oral haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral haloperidol 7.5-10 mg/day (n = 151)
Trial: 15374803
Drug: Oral L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-arginine therapy
Trial: 29773326
Drug: Tremelimumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (1 mg/kg bodyweight) and durvalumab (20 mg/kg bodyweight) every 4 weeks for four doses, followed by maintenance intravenous durvalumab at the same dose and schedule for nine doses
Trial: 10472344
Drug: Amifostine as
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amifostine as a bolus injection (200 mg/m2 dissolved in 10 ml sodium chloride 0.9%)
Trial: 10472344
Drug: Amifostine as
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amifostine as a bolus injection
Trial: 8709324
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg urapidil for 4 weeks (group 2)
Trial: 8709324
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg urapidil for 2 weeks followed by 60 mg for 2 weeks (group 3)
Trial: 1876628
Drug: Clonidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (2 micrograms/kg, single i.v. dose)
Trial: 6283753
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg penbutolol (pure S‐form)
Trial: 6283753
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg isopenbutolol (pure R‐form)
Trial: 25079477
Drug: Mg alginate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg alginate plus simethicone
Trial: 21700623
Drug: Single-dose oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oseltamivir in morbidly obese patients
Trial: 21700623
Drug: Single-dose oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oseltamivir in control (non-obese) subjects
Trial: 21700623
Drug: Single-dose oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oseltamivir carboxylate in morbidly obese patients
Trial: 21700623
Drug: Single-dose oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oseltamivir carboxylate in control (non-obese) subjects
Trial: 16739183
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment model (TTM)
Trial: 15520323
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg PO
Trial: 8098243
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg once-daily nebivolol
Trial: 8098243
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg once-daily nebivolol
Trial: 8098243
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg once-daily atenolol
Trial: 8098243
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg once-daily atenolol
Trial: 3632148
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal with prebound aspirin
Trial: 1360699
Drug: Wheat fibre
RxNorm normalized name: triticum (wheat fibre)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat fibre (16 g day-1)
Trial: 1360699
Drug: Ispaghula (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ispaghula (16 g day-1)
Trial: 6145726
Drug: Diazepam (15.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (15.8 mg)
Trial: 29402522
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/rosuvastatin 20 mg
Trial: 29402522
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/rosuvastatin 5 mg
Trial: 26965765
Drug: Low carbohydrate
RxNorm normalized name: Low carbohydrate beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low carbohydrate diet (75 g per day)
Trial: 16170182
Drug: Dacarbazine 250
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine 250 mg/m2 and cisplatin 30 mg/m2 combined with interferon‐alfa‐2b 10 x 10(6) U/m2 (arm A)
Trial: 16170182
Drug: Dacarbazine 250
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine 250 mg/m2 and cisplatin 30 mg/m2 combined with interferon‐alfa‐2b 10 x 10(6) U/m2 and IL-2 (arm B)
Trial: 11994348
Drug: Weekly injections
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly injections of testosterone (100 mg/wk)
Trial: 19667501
Drug: SSRIs (e.g.,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (e.g., paroxetine, citalopram)
Trial: 84260
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of vitamin C given daily for 28 days
Trial: 24783926
Drug: Five-element music
RxNorm normalized name: HISTA-FIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-element music therapy
Trial: 2544249
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy and Dactinomycin (Actinomycin D) + Vincristine + Adriamycin +/− Cyclophosphamide
Trial: 580761
Drug: Rifampicin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (oral dose, specific dosage not mentioned)
Trial: 580761
Drug: Increasing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing oral dose of rifampicin
Trial: 580761
Drug: Rifampicin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (oral dosage forms of the same nominal strength)
Trial: 31981713
Drug: High-dose rifapentine
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose rifapentine with moxifloxacin for four months
Trial: 31981713
Drug: High-dose rifapentine
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose rifapentine without moxifloxacin for four months
Trial: 31981713
Drug: Conventional six-month
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional six-month treatment regimen
Trial: 23240909
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of AS03‐adjuvanted A/California/7/2009 (H1N1) vaccine
Trial: 23240909
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of AS03‐adjuvanted A/California/7/2009 (H1N1) vaccine
Trial: 20860765
Drug: Informed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Informed therapy (group A)
Trial: 19531054
Drug: Repaglinide/metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide/metformin FDC BID
Trial: 19531054
Drug: Repaglinide/metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide/metformin FDC TID
Trial: 17327813
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (titrated doses)
Trial: 7529155
Drug: Plasma, serum,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma, serum, or immunoglobulin preparations from donors
Trial: 23481666
Drug: Chemokine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemokine and cytokine responses of peripheral blood mononuclear cells stimulated with TLR2, 4, or 7/8 agonists
Trial: 17206703
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg infliximab (IFX)
Trial: 17206703
Drug: 3-dose IFX
RxNorm normalized name: IFX-1
DrugBank: Vilobelimab (DB16416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose IFX induction at weeks 0, 2, and 6
Trial: 17206703
Drug: Infliximab (IFX)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (IFX) for acute steroid-refractory colitis
Trial: 11238498
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (80-microg patches) + oral norethisterone (1 mg daily)
Trial: 9755259
Drug: xylitol syrup
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: xylitol syrup
Trial: 9755259
Drug: xylitol lozenge
RxNorm normalized name: xylitol Lozenge Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xylitol lozenge
Trial: 9755259
Drug: control syrup
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: control syrup
Trial: 9755259
Drug: control lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control lozenge
Trial: 3245292
Drug: Concentrated human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated human diploid cell vaccine (HDCV) with human rabies immune globulin (HRIG)
Trial: 3245292
Drug: Concentrated and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated and purified human diploid cell vaccine (HDCV) with human rabies immune globulin (HRIG)
Trial: 25151541
Drug: Natural oil-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural oil-based emulsion containing allantoin (cream 1)
Trial: 25151541
Drug: Aqueous cream
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous cream (cream 2)
Trial: 20033409
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (10 mg/kg/die for 3 days, then 2.5 mg/kg/die)
Trial: 20033409
Drug: Standard-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose methylprednisolone (1 mg/kg/die for 3 days, then 2.5 mg/kg/die)
Trial: 20033409
Drug: Standard-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose methylprednisolone
Trial: 15679716
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (BUD) 800 mug daily for 3 months
Trial: 10336792
Drug: Alprazolam (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0, 0.25, 0.50, 0.75 mg)
Trial: 27578365
Drug: Esketamine (Ketanest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine (Ketanest S®) administered intravenously during a 55 min resting-state fMRI scan
Trial: 22987083
Drug: Patupilone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patupilone (10 mg/m² intravenously every 3 weeks)
Trial: 22987083
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) (50 mg/m² intravenously every 4 weeks)
Trial: 21246846
Drug: Abdominal acupuncture
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal acupuncture plus Long's bone-setting manipulation (combined therapy)
Trial: 12887127
Drug: HRT (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (0.625 mg of conjugated equine estrogen combined with 2.5 mg of medroxyprogesterone acetate) for 12 months in HT-HRT group
Trial: 12887127
Drug: HRT (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (0.625 mg of conjugated equine estrogen combined with 2.5 mg of medroxyprogesterone acetate) for 12 months in NT-HRT group
Trial: 10365610
Drug: Mivacurium (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium (0.25 mg/kg; 3 x SD95)
Trial: 8370422
Drug: NOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOP regimen (mitoxantrone 16 mg/m2, vincristine 2 mg, prednisolone 250 mg day 1-4 and 17-20)
Trial: 8370422
Drug: M+P regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M+P regimen (melphalan 0.25 mg/kg and prednisolone 100-200 mg/day day 1-4)
Trial: 31823654
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) with nivolumab
Trial: 31823654
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) with nivolumab and linrodostat mesylate
Trial: 19895770
Drug: Increased therapist
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased therapist structure during aftercare treatment
Trial: 15767638
Drug: High-dose cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide, cisplatin, and carmustine (HD-CPB) with stem-cell support
Trial: 15767638
Drug: Intermediate-dose cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose cyclophosphamide, cisplatin, and carmustine (ID-CPB) with G-CSF support
Trial: 15383197
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg levofloxacin
Trial: 9559801
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g levofloxacin
Trial: 8963007
Drug: Dimethyl ether-propane
RxNorm normalized name: DIMETHYL ETHER/PROPANE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethyl ether-propane cryogenic spray (DMEP)
Trial: 1858160
Drug: OKT3 for
RxNorm normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3 for the first 14 days after OLT with low-dose steroids
Trial: 1858160
Drug: Cyclosporine, steroids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine, steroids, and azathioprine
Trial: 6133803
Drug: Timiperone (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timiperone (1.0 mg/tablet, daily dose of 1-3 tablets for the first day, up to 12 tablets for 12 weeks)
Trial: 6133803
Drug: Haloperidol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (1.5 mg/tablet, daily dose of 1-3 tablets for the first day, up to 12 tablets for 12 weeks)
Trial: 30101824
Drug: Etilefrine 2
RxNorm normalized name: etilefrine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etilefrine 2 mg
Trial: 22527894
Drug: Hyaluronan-enriched transfer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronan-enriched transfer medium (HETM) (0.5 mg/ml hyaluronan)
Trial: 19172627
Drug: Dex‐P (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dex‐P (4 mg/ml) continuously applied for 14 days via a round window catheter
Trial: 19172627
Drug: Dex‐P (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dex‐P (4 mg/ml) after 3 months follow-up
Trial: 19172627
Drug: Dex‐P (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dex‐P (4 mg/ml)
Trial: 12420185
Drug: Tinnitus Retraining
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinnitus Retraining Therapy combined with cognitive behavioral group therapy
Trial: 12420185
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral group therapy alone
Trial: 7917733
Drug: Preoperative multimodal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative multimodal analgesia regimen (morphine 0.15 mg kg‐1 i.m., perphenazine 0.03 mg kg‐1 i.m., indomethacin 100 mg rectal suppository)
Trial: 7917733
Drug: Placebo (midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (midazolam 0.05 mg kg‐1 i.m. and placebo rectal suppository)
Trial: 1632399
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (treatment and placebo)
Trial: 2060256
Drug: Ibuprofen 100
RxNorm normalized name: ibuprofen 100 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 100 mg + Caffeine 100 mg